Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 598 entries
Sorted by: Best Match Show Resources per page
The role of pharmacoepidemiology in pharmacovigilance: a conference at the 6th ESOP Meeting, Budapest, 28 September 1998.

Pharmacoepidemiology and drug safety

Abenhaim L, Moore N, Bégaud B.
PMID: 15073881
Pharmacoepidemiol Drug Saf. 1999 Apr;8:S1-7. doi: 10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-5.

No abstract available.

Cite
Abenhaim L, Moore N, Bégaud B. The role of pharmacoepidemiology in pharmacovigilance: a conference at the 6th ESOP Meeting, Budapest, 28 September 1998. Pharmacoepidemiol Drug Saf. 1999;8:S1-7doi: 10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-5.
Abenhaim, L., Moore, N., & Bégaud, B. (1999). The role of pharmacoepidemiology in pharmacovigilance: a conference at the 6th ESOP Meeting, Budapest, 28 September 1998. Pharmacoepidemiology and drug safety, 8S1-7. https://doi.org/10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-5
Abenhaim, L, et al. "The role of pharmacoepidemiology in pharmacovigilance: a conference at the 6th ESOP Meeting, Budapest, 28 September 1998." Pharmacoepidemiology and drug safety vol. 8 (1999): S1-7. doi: https://doi.org/10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-5
Abenhaim L, Moore N, Bégaud B. The role of pharmacoepidemiology in pharmacovigilance: a conference at the 6th ESOP Meeting, Budapest, 28 September 1998. Pharmacoepidemiol Drug Saf. 1999 Apr;8:S1-7. doi: 10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-5. PMID: 15073881.
Copy Download .nbib Format: NLM
The use of newly marketed drugs in children and adolescents prescribed in general practice.

Pharmacoepidemiology and drug safety

Wilton LV, Pearce G, Mann RD.
PMID: 15073885
Pharmacoepidemiol Drug Saf. 1999 Apr;8:S37-45. doi: 10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-0.

This study determined the licensed and 'off label' (outside the terms of the licence) use of newly marketed medicines in children (2-11 years) and adolescents (12-17 years), by general practitioners in England. In addition, the incidence rates during the...

Cite
Wilton LV, Pearce G, Mann RD. The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf. 1999;8:S37-45doi: 10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-0.
Wilton, L. V., Pearce, G., & Mann, R. D. (1999). The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiology and drug safety, 8S37-45. https://doi.org/10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-0
Wilton, L V, et al. "The use of newly marketed drugs in children and adolescents prescribed in general practice." Pharmacoepidemiology and drug safety vol. 8 (1999): S37-45. doi: https://doi.org/10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-0
Wilton LV, Pearce G, Mann RD. The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf. 1999 Apr;8:S37-45. doi: 10.1002/(sici)1099-1557(199904)8:1+3.3.co;2-0. PMID: 15073885.
Copy Download .nbib Format: NLM
The role of pharmacoepidemiology in pharmacovigilance: rational drug use in pregnancy.

Pharmacoepidemiology and drug safety

Czeizel AE.
PMID: 15073887
Pharmacoepidemiol Drug Saf. 1999 Apr;8:S55-61. doi: 10.1002/(SICI)1099-1557(199904)8:1+3.0.CO;2-1.

The most important objective of the Hungarian Case-Control Surveillance of Congenital Abnormalities is the postmarketing surveillance of the teratogenic effects of drugs. This dataset includes 22,865 pregnant women who had offspring with congenital abnormalities and 38,151 pregnant women who...

Cite
Czeizel AE. The role of pharmacoepidemiology in pharmacovigilance: rational drug use in pregnancy. Pharmacoepidemiol Drug Saf. 1999;8:S55-61doi: 10.1002/(SICI)1099-1557(199904)8:1+3.0.CO;2-1.
Czeizel, A. E. (1999). The role of pharmacoepidemiology in pharmacovigilance: rational drug use in pregnancy. Pharmacoepidemiology and drug safety, 8S55-61. https://doi.org/10.1002/(SICI)1099-1557(199904)8:1+3.0.CO;2-1
Czeizel, A E. "The role of pharmacoepidemiology in pharmacovigilance: rational drug use in pregnancy." Pharmacoepidemiology and drug safety vol. 8 (1999): S55-61. doi: https://doi.org/10.1002/(SICI)1099-1557(199904)8:1+3.0.CO;2-1
Czeizel AE. The role of pharmacoepidemiology in pharmacovigilance: rational drug use in pregnancy. Pharmacoepidemiol Drug Saf. 1999 Apr;8:S55-61. doi: 10.1002/(SICI)1099-1557(199904)8:1+3.0.CO;2-1. PMID: 15073887.
Copy Download .nbib Format: NLM
Use of antituberculosis drugs in Spain 1996.

Pharmacoepidemiology and drug safety

Blázquez Pérez A, Mateos Campos RM.
PMID: 15073896
Pharmacoepidemiol Drug Saf. 1999 Dec;8(7):523-8. doi: 10.1002/(SICI)1099-1557(199912)8:7<523::AID-PDS459>3.0.CO;2-B.

PURPOSE: To determine and analyse the consumption of antituberculosis agents in Spain.METHODS: Pharmacoepidemiological study on the use of antituberculosis agents during 1996 using data from prescriptions redeemed by the National Health Service.RESULTS: During 1996, 5 533 233 defined daily...

Cite
Blázquez Pérez A, Mateos Campos RM. Use of antituberculosis drugs in Spain 1996. Pharmacoepidemiol Drug Saf. 1999;8(7):523-8doi: 10.1002/(SICI)1099-1557(199912)8:7<523::AID-PDS459>3.0.CO;2-B.
Blázquez Pérez, A., & Mateos Campos, R. M. (1999). Use of antituberculosis drugs in Spain 1996. Pharmacoepidemiology and drug safety, 8(7), 523-8. https://doi.org/10.1002/(SICI)1099-1557(199912)8:7<523::AID-PDS459>3.0.CO;2-B
Blázquez Pérez, A, and Mateos Campos, R M. "Use of antituberculosis drugs in Spain 1996." Pharmacoepidemiology and drug safety vol. 8,7 (1999): 523-8. doi: https://doi.org/10.1002/(SICI)1099-1557(199912)8:7<523::AID-PDS459>3.0.CO;2-B
Blázquez Pérez A, Mateos Campos RM. Use of antituberculosis drugs in Spain 1996. Pharmacoepidemiol Drug Saf. 1999 Dec;8(7):523-8. doi: 10.1002/(SICI)1099-1557(199912)8:7<523::AID-PDS459>3.0.CO;2-B. PMID: 15073896.
Copy Download .nbib Format: NLM
Self-report of symptom frequency and symptom distress in kidney transplant recipients.

Pharmacoepidemiology and drug safety

de Barros CT, Cabrita J.
PMID: 15073901
Pharmacoepidemiol Drug Saf. 1999 Oct;8(6):395-403. doi: 10.1002/(SICI)1099-1557(199910/11)8:6<395::AID-PDS449>3.0.CO;2-D.

OBJECTIVE: The aim of this study was to assess symptom frequency and symptom distress associated with adverse effects of immunosuppressive therapy in kidney transplant recipients and to correlate it with compliance and socio-demographic characteristics.METHODS: Symptom frequency and symptom distress...

Cite
de Barros CT, Cabrita J. Self-report of symptom frequency and symptom distress in kidney transplant recipients. Pharmacoepidemiol Drug Saf. 1999;8(6):395-403doi: 10.1002/(SICI)1099-1557(199910/11)8:6<395::AID-PDS449>3.0.CO;2-D.
de Barros, C. T., & Cabrita, J. (1999). Self-report of symptom frequency and symptom distress in kidney transplant recipients. Pharmacoepidemiology and drug safety, 8(6), 395-403. https://doi.org/10.1002/(SICI)1099-1557(199910/11)8:6<395::AID-PDS449>3.0.CO;2-D
de Barros, C T, and Cabrita, J. "Self-report of symptom frequency and symptom distress in kidney transplant recipients." Pharmacoepidemiology and drug safety vol. 8,6 (1999): 395-403. doi: https://doi.org/10.1002/(SICI)1099-1557(199910/11)8:6<395::AID-PDS449>3.0.CO;2-D
de Barros CT, Cabrita J. Self-report of symptom frequency and symptom distress in kidney transplant recipients. Pharmacoepidemiol Drug Saf. 1999 Oct;8(6):395-403. doi: 10.1002/(SICI)1099-1557(199910/11)8:6<395::AID-PDS449>3.0.CO;2-D. PMID: 15073901.
Copy Download .nbib Format: NLM
Tom Lasser.

Pharmacoepidemiology and drug safety

Beard K.
PMID: 15073908
Pharmacoepidemiol Drug Saf. 1999 Aug;8(5):323. doi: 10.1002/(SICI)1099-1557(199908/09)8:5<323::AID-PDS442>3.0.CO;2-M.

No abstract available.

Cite
Beard K. Tom Lasser. Pharmacoepidemiol Drug Saf. 1999;8(5):323doi: 10.1002/(SICI)1099-1557(199908/09)8:5<323::AID-PDS442>3.0.CO;2-M.
Beard, K. (1999). Tom Lasser. Pharmacoepidemiology and drug safety, 8(5), 323. https://doi.org/10.1002/(SICI)1099-1557(199908/09)8:5<323::AID-PDS442>3.0.CO;2-M
Beard, K. "Tom Lasser." Pharmacoepidemiology and drug safety vol. 8,5 (1999): 323. doi: https://doi.org/10.1002/(SICI)1099-1557(199908/09)8:5<323::AID-PDS442>3.0.CO;2-M
Beard K. Tom Lasser. Pharmacoepidemiol Drug Saf. 1999 Aug;8(5):323. doi: 10.1002/(SICI)1099-1557(199908/09)8:5<323::AID-PDS442>3.0.CO;2-M. PMID: 15073908.
Copy Download .nbib Format: NLM
Recall of a lead-contaminated vitamin and mineral supplement in a clinical trial.

Pharmacoepidemiology and drug safety

Rogan WJ, Ragan NB, Damokosh AI, Davoli C, Shaffer TR, Jones RL, Wilkens S, Heenehan MC, Ware JH, Henretig F.
PMID: 15073911
Pharmacoepidemiol Drug Saf. 1999 Aug;8(5):343-50. doi: 10.1002/(SICI)1099-1557(199908/09)8:5<343::AID-PDS440>3.0.CO;2-Q.

PURPOSE: The Treatment of Lead-exposed Children (TLC) trial tested whether developmental outcome differed between children treated for lead poisoning with succimer or placebo. On 7 July 1997, TLC was informed that the vitamin and mineral supplements it gave to...

Cite
Rogan WJ, Ragan NB, Damokosh AI, et al. Recall of a lead-contaminated vitamin and mineral supplement in a clinical trial. Pharmacoepidemiol Drug Saf. 1999;8(5):343-50doi: 10.1002/(SICI)1099-1557(199908/09)8:5<343::AID-PDS440>3.0.CO;2-Q.
Rogan, W. J., Ragan, N. B., Damokosh, A. I., Davoli, C., Shaffer, T. R., Jones, R. L., Wilkens, S., Heenehan, M. C., Ware, J. H., & Henretig, F. (1999). Recall of a lead-contaminated vitamin and mineral supplement in a clinical trial. Pharmacoepidemiology and drug safety, 8(5), 343-50. https://doi.org/10.1002/(SICI)1099-1557(199908/09)8:5<343::AID-PDS440>3.0.CO;2-Q
Rogan, W J, et al. "Recall of a lead-contaminated vitamin and mineral supplement in a clinical trial." Pharmacoepidemiology and drug safety vol. 8,5 (1999): 343-50. doi: https://doi.org/10.1002/(SICI)1099-1557(199908/09)8:5<343::AID-PDS440>3.0.CO;2-Q
Rogan WJ, Ragan NB, Damokosh AI, Davoli C, Shaffer TR, Jones RL, Wilkens S, Heenehan MC, Ware JH, Henretig F. Recall of a lead-contaminated vitamin and mineral supplement in a clinical trial. Pharmacoepidemiol Drug Saf. 1999 Aug;8(5):343-50. doi: 10.1002/(SICI)1099-1557(199908/09)8:5<343::AID-PDS440>3.0.CO;2-Q. PMID: 15073911.
Copy Download .nbib Format: NLM
Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.

Pharmacoepidemiology and drug safety

Duh MS, Walker AM, Kronlund KH.
PMID: 15073920
Pharmacoepidemiol Drug Saf. 1999 Jul;8(4):275-83. doi: 10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D.

OBJECTIVES: This study quantifies the incidence of liver enzyme abnormalities in the general population of central Massachusetts.METHODS: Computerized data files from a health maintenance organization were used to ascertain potential subjects during the study period of 1 July 1992-30...

Cite
Duh MS, Walker AM, Kronlund KH. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf. 1999;8(4):275-83doi: 10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D.
Duh, M. S., Walker, A. M., & Kronlund, K. H. (1999). Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiology and drug safety, 8(4), 275-83. https://doi.org/10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D
Duh, M S, et al. "Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts." Pharmacoepidemiology and drug safety vol. 8,4 (1999): 275-83. doi: https://doi.org/10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D
Duh MS, Walker AM, Kronlund KH. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf. 1999 Jul;8(4):275-83. doi: 10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D. PMID: 15073920.
Copy Download .nbib Format: NLM
Hospitalization rates as outcome indicators of national medicinal drug policies: the example of gastrointestinal ulcer.

Pharmacoepidemiology and drug safety

Roughead EE, Gilbert AL, Primrose JG, Sansom LN.
PMID: 15073922
Pharmacoepidemiol Drug Saf. 1999 Jul;8(4):291-9. doi: 10.1002/(SICI)1099-1557(199907)8:4<291::AID-PDS434>3.0.CO;2-V.

National medicinal drug policies are employed around the world as a means of maximizing the benefits of medication use. An essential component to the implementation of these policies is their concurrent evaluation, which informs future policy implementation and strategic...

Cite
Roughead EE, Gilbert AL, Primrose JG, et al. Hospitalization rates as outcome indicators of national medicinal drug policies: the example of gastrointestinal ulcer. Pharmacoepidemiol Drug Saf. 1999;8(4):291-9doi: 10.1002/(SICI)1099-1557(199907)8:4<291::AID-PDS434>3.0.CO;2-V.
Roughead, E. E., Gilbert, A. L., Primrose, J. G., & Sansom, L. N. (1999). Hospitalization rates as outcome indicators of national medicinal drug policies: the example of gastrointestinal ulcer. Pharmacoepidemiology and drug safety, 8(4), 291-9. https://doi.org/10.1002/(SICI)1099-1557(199907)8:4<291::AID-PDS434>3.0.CO;2-V
Roughead, E E, et al. "Hospitalization rates as outcome indicators of national medicinal drug policies: the example of gastrointestinal ulcer." Pharmacoepidemiology and drug safety vol. 8,4 (1999): 291-9. doi: https://doi.org/10.1002/(SICI)1099-1557(199907)8:4<291::AID-PDS434>3.0.CO;2-V
Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Hospitalization rates as outcome indicators of national medicinal drug policies: the example of gastrointestinal ulcer. Pharmacoepidemiol Drug Saf. 1999 Jul;8(4):291-9. doi: 10.1002/(SICI)1099-1557(199907)8:4<291::AID-PDS434>3.0.CO;2-V. PMID: 15073922.
Copy Download .nbib Format: NLM
Prescribed daily doses and 'risk factors' associated with the use of benzodiazepines in primary care.

Pharmacoepidemiology and drug safety

de las Cuevas C, Sanz E, de la Fuente JA, Cabrera C, Mateos A.
PMID: 15073930
Pharmacoepidemiol Drug Saf. 1999 May;8(3):207-16. doi: 10.1002/(SICI)1099-1557(199905/06)8:3<207::AID-PDS421>3.0.CO;2-1.

OBJECTIVE: To assess the extent, characteristics and determinants of benzodiazepine prescription in outpatient Primary Health Care.METHODS: A clinical audit of a stratified random sample of Primary Health Care Centres in the seven islands and 1.6 million inhabitants region of...

Cite
de las Cuevas C, Sanz E, de la Fuente JA, et al. Prescribed daily doses and 'risk factors' associated with the use of benzodiazepines in primary care. Pharmacoepidemiol Drug Saf. 1999;8(3):207-16doi: 10.1002/(SICI)1099-1557(199905/06)8:3<207::AID-PDS421>3.0.CO;2-1.
de las Cuevas, C., Sanz, E., de la Fuente, J. A., Cabrera, C., & Mateos, A. (1999). Prescribed daily doses and 'risk factors' associated with the use of benzodiazepines in primary care. Pharmacoepidemiology and drug safety, 8(3), 207-16. https://doi.org/10.1002/(SICI)1099-1557(199905/06)8:3<207::AID-PDS421>3.0.CO;2-1
de las Cuevas, C, et al. "Prescribed daily doses and 'risk factors' associated with the use of benzodiazepines in primary care." Pharmacoepidemiology and drug safety vol. 8,3 (1999): 207-16. doi: https://doi.org/10.1002/(SICI)1099-1557(199905/06)8:3<207::AID-PDS421>3.0.CO;2-1
de las Cuevas C, Sanz E, de la Fuente JA, Cabrera C, Mateos A. Prescribed daily doses and 'risk factors' associated with the use of benzodiazepines in primary care. Pharmacoepidemiol Drug Saf. 1999 May;8(3):207-16. doi: 10.1002/(SICI)1099-1557(199905/06)8:3<207::AID-PDS421>3.0.CO;2-1. PMID: 15073930.
Copy Download .nbib Format: NLM
Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders.

Pharmacoepidemiology and drug safety

[No authors listed]
PMID: 15073931
Pharmacoepidemiol Drug Saf. 1999 May;8(3):217-24. doi: 10.1002/(SICI)1099-1557(199905/06)8:3<217::AID-PDS415>3.0.CO;2-Q.

This paper is the report of a meeting held in Geneva under the auspices of the Council for International Organizations of Medical Sciences (CIOMS) on 27-28 October 1998. It contains definitions of terms used in reporting adverse drug reactions...

Cite
Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders. Pharmacoepidemiol Drug Saf. 1999;8(3):217-24doi: 10.1002/(SICI)1099-1557(199905/06)8:3<217::AID-PDS415>3.0.CO;2-Q.
(1999). Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders. Pharmacoepidemiology and drug safety, 8(3), 217-24. https://doi.org/10.1002/(SICI)1099-1557(199905/06)8:3<217::AID-PDS415>3.0.CO;2-Q
"Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders." Pharmacoepidemiology and drug safety vol. 8,3 (1999): 217-24. doi: https://doi.org/10.1002/(SICI)1099-1557(199905/06)8:3<217::AID-PDS415>3.0.CO;2-Q
Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders. Pharmacoepidemiol Drug Saf. 1999 May;8(3):217-24. doi: 10.1002/(SICI)1099-1557(199905/06)8:3<217::AID-PDS415>3.0.CO;2-Q. PMID: 15073931.
Copy Download .nbib Format: NLM
Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case.

Pharmacoepidemiology and drug safety

Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA.
PMID: 15073933
Pharmacoepidemiol Drug Saf. 1999 Mar;8(2):81-94. doi: 10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G.

A retrospective cohort study was performed to determine the incidence of hypoprothrombinaemia and bleeding in patients receiving cefoperazone, a third-generation cephalosporin that contains an NMTT side chain. 374 patients receiving cefoperazone from February 1983 to March 1986 at a...

Cite
Strom BL, Schinnar R, Gibson GA, et al. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. 1999;8(2):81-94doi: 10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G.
Strom, B. L., Schinnar, R., Gibson, G. A., Brennan, P. J., & Berlin, J. A. (1999). Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiology and drug safety, 8(2), 81-94. https://doi.org/10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G
Strom, B L, et al. "Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case." Pharmacoepidemiology and drug safety vol. 8,2 (1999): 81-94. doi: https://doi.org/10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G
Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf. 1999 Mar;8(2):81-94. doi: 10.1002/(SICI)1099-1557(199903/04)8:2<81::AID-PDS411>3.0.CO;2-G. PMID: 15073933.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 598 entries